Shopping Cart
Remove All
Your shopping cart is currently empty
SB-265610 (GSK-CXCR2) is a nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis (IC50s: 3.7 nM and 70 nM, respectively).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $51 | In Stock | In Stock | |
| 5 mg | $122 | In Stock | In Stock | |
| 10 mg | $197 | In Stock | In Stock | |
| 25 mg | $396 | In Stock | In Stock | |
| 50 mg | $589 | In Stock | In Stock | |
| 100 mg | $843 | In Stock | In Stock | |
| 500 mg | $1,730 | In Stock | - | |
| 1 mL x 10 mM (in DMSO) | $133 | In Stock | In Stock |
| Description | SB-265610 (GSK-CXCR2) is a nonpeptide and allosteric CXCR2 antagonist. SB-265610 blocks rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization and neutrophil chemotaxis (IC50s: 3.7 nM and 70 nM, respectively). |
| Targets&IC50 | CXCR2 (neutrophil chemotaxis):70 nM, CXCR2 (CINC-1-induced calcium mobilization):3.7 nM |
| In vitro | SB-265610 decreases the antiapoptotic effect of CINC-1 to the levels of those untreated with CINC-1. SB-265610 antagonizes rat cytokine-induced neutrophil chemoattractant-1 (CINC-1)-induced calcium mobilization (IC50 of 3.7 nM) and rat neutrophil chemotaxis in a concentration-dependent manner (IC50 of 70 nM) [1]. |
| In vivo | SB-265610 (100 mg/kg/day;p.o; daily; for 5 days; CXCR2 wild type mice) treatment markedly delays healing parameters in CXCR2 wild type mice during the wound repair process[2]. |
| Synonyms | GSK-CXCR2 |
| Molecular Weight | 357.16 |
| Formula | C14H9BrN6O |
| Cas No. | 211096-49-0 |
| Smiles | Brc1ccccc1NC(=O)Nc1ccc(C#N)c2nn[nH]c12 |
| Relative Density. | 1.77 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 66 mg/mL (184.79 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.6 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.